From: Cellular immunotherapy for refractory hematological malignancies
Recipient eligibility criteria | Â |
---|---|
Inclusion Criteria | Age ≥ 18 |
 | Histologic confirmation of the following leukemias/lymphomas: |
• Mantle cell lymphoma with Ki-67>30% | |
• Diffuse Large Cell Lymphoma | |
• Burkitts Lymphoma | |
• Systemic T Cell Lymphomas | |
• Acute Myeloid Leukemia | |
• Acute Lymphoblastic Leukemia | |
 | Recurrence or progression of disease after at least 1 prior standard treatment |
 | Progression of disease within 6 months of last treatment |
 | No available curative treatment option |
 | ≥ 4-weeks since prior chemotherapy or radiation (Exception: Hydroxyurea may be utilized up to 48 hours prior to treatment) |
 | Life expectancy of 2 months at treatment initiation |
 | ≥ 6 months post autologous stem cell transplant |
 | DLCO ≥ 40% with no symptomatic pulmonary disease. |
 | LVEF ≥ 40% by MUGA or echocardiogram. |
 | Creatinine ≤ 2.0 mg/dl, Total bilirubin <1.5x the upper limit of normal (ULN), AST < 3x ULN |
 | Non-pregnant and willing to use appropriate birth control during study period |
Exclusion criteria | Previous allogeneic stem cell transplant |
 | Previous purine analog (fludarabine, pentostatin, 2-CDA) or alemtuzumab within 1 year of entering the study |
 | CML, CLL, multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma) |
 | HLA antibodies to donor HLA type |
 | HIV-1 or 2 positive |
 | Oxygen dependant COPD |
 | Failure to demonstrate adequate compliance with medical therapy and follow-up |
 | Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy |
 | Active systemic infection |